Hospital treatment of community acquired pneumonia in children with penicillin Source: Annual Congress 2009 - Bacterial infections of upper and lower respiratory tract in childhood Year: 2009
Amoxicillin with clavulanic acid in empiric therapy of community acquired pneumonia - retrospective analysis Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005
Prevalence of penicillin resistant pneumococci among children with community acquired pneumonia admitted in a secondary reference hospital – 5 year study Source: Eur Respir J 2006; 28: Suppl. 50, 494s Year: 2006
Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin Source: Eur Respir J 2003; 22: Suppl. 45, 543s Year: 2003
Our experiences with cefriaxone in the treatment of hospital acquired pneumonias (HAP) Source: Eur Respir J 2002; 20: Suppl. 38, 357s Year: 2002
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Comparisom between imipenem/cilastatin and cefepim for treatment of severe nosocomial pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007
Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
The efficiency of levofloxacin in the therapy of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 5s Year: 2006
Initial intravenous antibiotic regimen in patients hospitalized for community acquired pneumonia (CAP) in France Source: Eur Respir J 2003; 22: Suppl. 45, 151s Year: 2003
Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007
Cost-efficacy analysis of cefixime switch therapy in the treatment of community acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006
Empiric penicillin monotherapy of CAP is not associated with increased mortality; experiences from the retrospective CAP-North cohort Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016
Prevention of MRSA pneumonia by oral vancomycin decontamination: a randomised trial Source: Eur Respir J 2004; 23: 921-926 Year: 2004
Randomised controlled trial of sequential intravenous and oral azithromycin compared with intravenous ceftriaxone followed by cefixime both in combination with clarithromycin in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare Source: Eur Respir J 2002; 20: Suppl. 38, 561s Year: 2002
Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008
The extent of microbiological testing and antibiotic de-escalation in adults with community-acquired pneumonia: a retrospective cohort study. Source: International Congress 2018 – Predicting the future: biomarkers of respiratory infection Year: 2018
Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007
Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis Source: Eur Respir J 2010; 35: 858-864 Year: 2010